PUBLISHED DATE : Jul 2022 | Pages : 274
Fill out your details & get your free sample
The Global Viral Transport Medium Market Size, Share, Growth, And Trends Analysis Report By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2022–2027.
274 Pages
157 Tables
111 Charts
5 Regions
18 Countries
45 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 5.6 billion |
| CAGR (2022-2027) | (3.51%) |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Product, Usage, Indication, End-User, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, France, Italy, Germany, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, and South Africa |
The viral transport medium market is expected to grow at a CAGR of 4% from 2026 to 2027 and is projected to reach $5 billion in 2027. The sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits. With the fast spread of the COVID-19 virus, many countries prioritized diagnostic testing for quick diagnosis of the virus. This fuelled the exponential increase in demand for VTM kits for sample collection from suspected COVID-19 patients. Owing to the surge in demand for diagnostic tests and sample collection from people, many vendors increased their production. They continuously tried to deliver many viral transport media kits to meet the exponential demand for COVID-19 diagnostic tests. In March 2020, increased demand for covid-19 testing led to a global shortage of nasopharyngeal swabs and viral transport medium test kits that significantly impacted large-scale testing efforts.
Viral transport media are the medical kits, swabs, and tubes used to collect, preserve, and transport viral specimens for research and diagnostic tests, which exist in several formulations, consisting of a buffered salt solution, a complex source of protein and amino acids, and anti-microbial agents. It preserves viruses and is either used for amplification by nucleic acid amplification testing (NAAT) technology or viral culture. It allows research collection, preservation, and transportation of viral specimens, including conventional cell culture methods, molecular biology techniques, and diagnostic tests. The importance of viral transport medium was known globally when a new H1N1 influenza virus was identified, causing the world's first flu pandemic in more than 40 years. Since then, it has been used majorly by hospitals, labs, and academic/research institutes for transporting viral samples across the research and clinical value chain. During the transport, the virus, if present, in the sample specimen should remain intact until the testing is completed.
Suddenly increased SARS-COV-2 infection rate drive substantial demand for VTM kits. It resulted in increased manufacturing and manufacturing capacity of the vendors. Most of the leading and emerging companies fulfilled the supply across the healthcare system in the world. In 2020, Thermo Fisher Scientific, one of the leading suppliers of viral transport kits, invested around $40 million in Lenexa and Kansas manufacturing facilities to scale up the production of the kits.
The pandemic increased the manufacturing of VTM kits globally and gave emerging market players new opportunities. Several new entries and new products were launched in the same period. Most of the global market players looked for a maximum supply of these kits; on the other side, newcomers entered with new products.
Viral transport medium kits are constantly in demand due to the increasing prevalence of infectious diseases. Viral infections are one of the major burdens seen during the pandemic period. The rising prevalence of viral infectious diseases enabled the growth of viral transport media kits. Some of the viral infectious diseases are Covid-19, influenza virus, enterovirus D68, herpes, varicella, RSV, etc. In diagnosing the diseases mentioned above, collection of samples, preservation, and transportation are required, whereas VTM kits are practitioners' most prominently used solutions. According to the Plos One article 2021, based on studies documented from 2007 to 2020, the overall prevalence of respiratory syncytial virus was around 11%, and adenovirus accounted for 13%. Influenza viral infection accounts high burden worldwide, which requires diagnosis and testing.
Non-polio enterovirus causes around 10-15 million infection cases annually & on the other side, 10,000 hospitalizations each year in the US. On the other side, herpes is one of the severe viral infectious conditions that demand laboratory testing for diagnosis and cure. It is categorized into the herpes simplex virus type 1 and herpes simplex virus type 2. It is a sexually transmitted infection that is present lifelong. Around 3.7 billion people under 50 suffer from HSV-1 and 491 million from HSV-2 under the age of 15–49-year-old.
Conversely, increasing the diagnosis rate for viral infectious diseases constantly drives the market growth. The increasing diagnosis rate of viral diseases requires laboratory testing of clinical specimens to identify the virus, viral antigens, and antibodies. In the last form, two decades major revolution was addressed in virus diagnostic laboratories. Also, the rapid increase in the aging population, the rise in the number of people undergoing various voluntary surgeries, and other factors have accelerated the requirement for various diagnostic tests that involve VTM kits. With the rising prevalence of various acute and chronic diseases worldwide, the number of surgeries performed to treat such diseases is also increasing rapidly.
A surge in Mass Testing for COVID-19 & Influenza
The demand for viral transport has increased exponentially during the COVID-19 pandemic. With academic/research institutes intensifying their experiments for developing vaccines and mass testing to stop the spread of COVID-19 globally, vendors have increased their manufacturing capacities and produced billions of VTM kits. Companies focus on innovation and developing kits containing double-ended flocked swabs, vials, antibiotics, and other items that inhibit microbial contamination. In addition, with the continuous increase of seasonal flu cases, manufacturers are also manufacturing viral transport for influenza tests, owing to influenza-related morbidity and mortality in many countries.
In 2021, the viral transport media segment accounted for a revenue share of 46% in the global viral transport medium market and dominated other segments. The universal transport media segment accounted for 34%, and the molecular transport media segment accounted for 20% market share in 2021. Molecular transport media experienced high demand during the SARS-COV-2 pandemic. It is used to collect samples of SARS-COV-2, HIV, RSV, influenza, and TB.
The rising diagnosis rate of covid-19 cases drives significant market growth by diagnosing severe SARS-COV-2 infection. In 2021, the diagnosis segment accounted for a revenue share of 67.44% in the global viral transport media market and showed dominance over the pre-clinical testing segment.
Influenza is one of the most common viral infections globally. In the global Viral Transport Medium Market, influenza & covid-19 indication segment accounted for 73.09% market share in 2021. The higher infection rate of Covid-19 across the world dominated the market with a higher market share.
In 2021, the lab's segment accounted for a revenue share of 40.30% in the global viral transport media market and dominated to other two segments. An increasing number of microbiology labs, research labs, biotech labs, and pharmaceutical and biotech company/ organizational labs drive viral transport kits' adoption and contribute to the market growth with dominance over other segments.
The market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa region. In North America, a high number of laboratory tests were registered during the pandemic, fueling market growth. On the other side, the presence of biopharma companies, a high number of labs, well-developed healthcare services, and research studies on viral infection drives significant market growth in the region and accounted 33.18% higher market share. Apart from the Covid-19 pandemic burden, other viral infections such as influenza, herpes, varicella, respiratory syncytial virus, and other viral infectious diseases demand the diagnosis where VTM kits play a vital role in the collection, preservation, and transportation of specimens. The rising prevalence of viral infection worldwide delivers high demand for VTM kits. Influenza viral infections continue to increase in African, North America, and Asia Pacific regions.
The global viral transport medium market is highly competitive in nature due to the presence of domestic, regional, and international market players. Also, the geographical presence of key market players and their broad distribution channels increases market competitiveness through their major supply, import, and export strategies. The outbreak of the COVID-19 pandemic significantly increased demand for VTM kits, driving high export and import of VTM kits from different countries through major market players. Vendors are increasing efforts to manufacture VTM products as per regulatory bodies' requirements. For instance, Hardy Diagnostics, an FDA-licensed manufacturer of medical devices for microbiological testing, launched the Universal Transport Medium, which is suitable for the collection, maintenance, and long-term freeze storage of clinical specimens. Apart from hospital and retail pharmacies, vendors also offer huge volumes of orders from online pharmacies. Hence, they collaborate with e-commerce companies to increase their sales and revenue options.
Puritan Medical Products, Thermo Fisher Scientific, BD (Becton Dickinson), Laboratory Corporation of America, Hardy Diagnostics, Vircell, and Himedia Laboratories are some of the leading market players engaged in the manufacturing and supplying VTM kits in the global viral transport medium market. Many new, local, and regional players have increased market competitiveness.
Frequently Asked Questions
HOW BIG IS THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
The global viral transport medium market is expected to reach USD 5.6 billion by 2027.
WHO ARE THE MAJOR PLAYERS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
BD (Beckton Dickinson), Hardy Diagnostics, HiMedia Laboratories, Laboratory Corporation of America, Puritan Medical Products, Thermo Fisher Scientific, and Vircell.
WHAT ARE THE GROWTH FACTORS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?
Increasing prevalence of infectious disease, diagnosis rates for viral infectious diseases, and a surge in covid-19 infections are the major growth factors in the global viral transport medium market.
WHAT ARE SOME OF THE LATEST TRENDS THAT WILL SHAPE THE FUTURE OF THE GLOBAL VTM MARKET?
Launches of new products and entry of new market players are the latest trends shaping the future of the global VTM market.
WHICH REGION IS EXPECTED TO OBSERVE THE LARGEST SHARE IN THE VIRAL TRANSPORT MEDIUM MARKET?
North America holds the largest share in the VTM market.
The global viral transport medium market is expected to reach USD 5.6 billion by 2027, observing a growth rate of 4% by 2026-2027.
The following factors driving the market growth are:
Base Year: 2021
Forecast Year: 2022-2027
Key Vendors
Other Prominent Vendors
Segmentation by Products
Segmentation by Usage
Segmentation by Indication
Segmentation by End-User
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 MARKET OPPORTUNITIES & TRENDS
8.1 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION
8.2 LAUNCH OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS
9 MARKET GROWTH ENABLERS
9.1 INCREASING PREVALENCE OF VIRAL INFECTIOUS DISEASES
9.2 SURGE IN COVID-19 INFECTIONS
9.3 INCREASE IN DIAGNOSIS OF VIRAL INFECTIOUS DISEASES
10 MARKET RESTRAINTS
10.1 VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS
10.2 FALSE-NEGATIVE RESULTS IN BORDERLINE CASES
10.3 LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 PRODUCTS
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 VIRAL TRANSPORT MEDIA
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 MARKET BY GEOGRAPHY
12.4 UNIVERSAL TRANSPORT MEDIA
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 MARKET BY GEOGRAPHY
12.5 MOLECULAR TRANSPORT MEDIA
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 MARKET BY GEOGRAPHY
13 USAGE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 DIAGNOSIS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 PRE-CLINICAL TESTING
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
14 INDICATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 INFLUENZA & COVID-19
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 HERPES SIMPLEX VIRUS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 RESPIRATORY SYNCYTIAL VIRUS (RSV)
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 VARICELLA-ZOSTER
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 OTHERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 LABS
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 HOSPITALS & CLINICS
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
15.5 OTHERS
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 MARKET BY GEOGRAPHY
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 PRODUCT
17.3.1 MARKET SIZE & FORECAST
17.4 USAGE
17.4.1 MARKET SIZE & FORECAST
17.5 INDICATION
17.5.1 MARKET SIZE & FORECAST
17.6 END-USER
17.6.1 MARKET SIZE & FORECAST
17.7 KEY COUNTRIES
17.7.1 US: MARKET SIZE & FORECAST
17.7.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 PRODUCT
18.3.1 MARKET SIZE & FORECAST
18.4 USAGE
18.4.1 MARKET SIZE & FORECAST
18.5 INDICATION
18.5.1 MARKET SIZE & FORECAST
18.6 END-USER
18.6.1 MARKET SIZE & FORECAST
18.7 KEY COUNTRIES
18.7.1 UK: MARKET SIZE & FORECAST
18.7.2 FRANCE: MARKET SIZE & FORECAST
18.7.3 ITALY: MARKET SIZE & FORECAST
18.7.4 GERMANY: MARKET SIZE & FORECAST
18.7.5 SPAIN: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 PRODUCT
19.3.1 MARKET SIZE & FORECAST
19.4 USAGE
19.4.1 MARKET SIZE & FORECAST
19.5 INDICATION
19.5.1 MARKET SIZE & FORECAST
19.6 END-USER
19.6.1 MARKET SIZE & FORECAST
19.7 KEY COUNTRIES
19.7.1 CHINA: MARKET SIZE & FORECAST
19.7.2 JAPAN: MARKET SIZE & FORECAST
19.7.3 INDIA: MARKET SIZE & FORECAST
19.7.4 AUSTRALIA: MARKET SIZE & FORECAST
19.7.5 SOUTH KOREA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 PRODUCT
20.3.1 MARKET SIZE & FORECAST
20.4 USAGE
20.4.1 MARKET SIZE & FORECAST
20.5 INDICATION
20.5.1 MARKET SIZE & FORECAST
20.6 END-USER
20.6.1 MARKET SIZE & FORECAST
20.7 KEY COUNTRIES
20.7.1 BRAZIL: MARKET SIZE & FORECAST
20.7.2 MEXICO: MARKET SIZE & FORECAST
20.7.3 ARGENTINA: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 PRODUCT
21.3.1 MARKET SIZE & FORECAST
21.4 USAGE
21.4.1 MARKET SIZE & FORECAST
21.5 INDICATION
21.5.1 MARKET SIZE & FORECAST
21.6 USAGE
21.6.1 MARKET SIZE & FORECAST
21.7 END-USER
21.7.1 MARKET SIZE & FORECAST
21.8 KEY COUNTRIES
21.8.1 TURKEY: MARKET SIZE & FORECAST
21.8.2 SAUDI ARABIA: MARKET SIZE & FORECAST
21.8.3 SOUTH AFRICA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
23 KEY COMPANY PROFILES
23.1 BD (BECTON DICKINSON)
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 HARDY DIAGNOSTICS
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 HIMEDIA LABORATORIES
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 LABORATORY CORPORATION OF AMERICA
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 PURITAN MEDICAL PRODUCTS
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 THERMO FISHER SCIENTIFIC
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.7 VIRCELL
23.7.1 BUSINESS OVERVIEW
23.7.2 PRODUCT OFFERINGS
23.7.3 KEY STRATEGIES
23.7.4 KEY STRENGTHS
23.7.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 AB MEDICAL
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 ACCUGENE USA
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 APICAL SCIENTIFIC
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERING
24.4 AZOOKA LABS
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERING
24.5 BIOMED DIAGNOSTICS
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 BIOBOAVISTA
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 BIOGENEX LABORATORIES
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 BIOLOGIX GROUP
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 BIOCOMMA
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 CHARM SCIENCES
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
24.11 CREATIVE LIFE SCIENCES CO. LTD.
24.11.1 BUSINESS OVERVIEW
24.11.2 PRODUCT OFFERINGS
24.12 CITOTEST LABWARE MANUFACTURING
24.12.1 BUSINESS OVERVIEW
24.12.2 PRODUCT OFFERINGS
24.13 CPT MEDICAL
24.13.1 BUSINESS OVERVIEW
24.13.2 PRODUCT OFFERINGS
24.14 COPAN DIAGNOSTIC INC.
24.14.1 BUSINESS OVERVIEW
24.14.2 PRODUCT OFFERINGS
24.15 DIASORIN MOLECULAR
24.15.1 BUSINESS OVERVIEW
24.15.2 PRODUCT OFFERINGS
24.16 EKF DIAGNOSTICS HOLDINGS PLC
24.16.1 BUSINESS OVERVIEW
24.16.2 PRODUCT OFFERINGS
24.17 ENSOL BIOSCIENCES
24.17.1 BUSINESS OVERVIEW
24.17.2 PRODUCT OFFERINGS
24.18 GEMINI BIOPRODUCTS
24.18.1 BUSINESS OVERVIEW
24.18.2 PRODUCT OFFERINGS
24.19 GENERAL BIOLOGICS
24.19.1 BUSINESS OVERVIEW
24.19.2 PRODUCT OFFERINGS
24.20 GENTUERI
24.20.1 BUSINESS OVERVIEW
24.20.2 PRODUCT OFFERINGS
24.21 GENESIS LIFETECH MARKETING
24.21.1 BUSINESS OVERVIEW
24.21.2 PRODUCT OFFERINGS
24.22 HAN CHANG MEDIC
24.22.1 BUSINESS OVERVIEW
24.22.2 PRODUCT OFFERINGS
24.23 HEBEI CHAORAN MEDICAL INSTRUMENTS
24.23.1 BUSINESS OVERVIEW
24.23.2 PRODUCT OFFERING
24.24 KSL DIAGNOSTICS
24.24.1 BUSINESS OVERVIEW
24.24.2 PRODUCT OFFERING
24.25 LUCENCE HEALTH
24.25.1 BUSINESS OVERVIEW
24.25.2 PRODUCT OFFERINGS
24.26 LAUNCHWORKS
24.26.1 BUSINESS OVERVIEW
24.26.2 PRODUCT OFFERING
24.27 LIOFILCHEM
24.27.1 BUSINESS OVERVIEW
24.27.2 PRODUCT OFFERING
24.28 MEDICAL WIRE & EQUIPMENT (MWE)
24.28.1 BUSINESS OVERVIEW
24.28.2 PRODUCT OFFERINGS
24.29 MIRACLEAN TECHNOLOGY
24.29.1 BUSINESS OVERVIEW
24.29.2 PRODUCT OFFERINGS
24.30 METADESIGN SOLUTIONS
24.30.1 BUSINESS OVERVIEW
24.30.2 PRODUCT OFFERINGS
24.31 MANILA HEALTHTEK
24.31.1 BUSINESS OVERVIEW
24.31.2 PRODUCT OFFERING
24.32 MATTEK
24.32.1 BUSINESS OVERVIEW
24.32.2 PRODUCT OFFERING
24.33 NODFORD INTERNATIONAL
24.33.1 BUSINESS OVERVIEW
24.33.2 PRODUCT OFFERING
24.34 STARPLEX SCIENTIFIC
24.34.1 BUSINESS OVERVIEW
24.34.2 PRODUCT OFFERINGS
24.35 SANSURE BIOTECH
24.35.1 BUSINESS OVERVIEW
24.35.2 PRODUCT OFFERINGS
24.36 TITAN BIOTECH
24.36.1 BUSINESS OVERVIEW
24.36.2 PRODUCT OFFERINGS
24.37 VEGAS BIOTECH
24.37.1 BUSINESS OVERVIEW
24.37.2 PRODUCT OFFERING
24.38 ZYBIO
24.38.1 BUSINESS OVERVIEW
24.38.2 PRODUCT OFFERING
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 MARKET BY GEOGRAPHY
26.2 MARKET BY PRODUCT
26.3 MARKET BY USAGE
26.4 MARKET BY INDICATION
26.5 MARKET BY END-USER
26.6 PRODUCT: MARKET BY GEOGRAPHY
26.6.1 VIRAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY
26.6.2 UNIVERSAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY
26.6.3 MOLECULAR TRANSPORT MEDIA: MARKET BY GEOGRAPHY
26.7 USAGE: MARKET BY GEOGRAPHY
26.7.1 DIAGNOSIS: MARKET BY GEOGRAPHY
26.7.2 PRE-CLINICAL TESTING: MARKET BY GEOGRAPHY
26.8 INDICATION: MARKET BY GEOGRAPHY
26.8.1 INFLUENZA & COVID-19: MARKET BY GEOGRAPHY
26.8.2 HERPES: MARKET BY GEOGRAPHY
26.8.3 RESPIRATORY SYNCYTIAL VIRUS: MARKET BY GEOGRAPHY
26.8.4 VARICELLA ZOSTER VIRUS: MARKET BY GEOGRAPHY
26.8.5 OTHER INDICATIONS: MARKET BY GEOGRAPHY
26.9 END-USER: MARKET BY GEOGRAPHY
26.9.1 LABS: MARKET BY GEOGRAPHY
26.9.2 HOSPITALS & CLINICS: MARKET BY GEOGRAPHY
26.9.3 OTHER INDICATION: MARKET BY GEOGRAPHY
27 APPENDIX
27.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL VIRAL TRANSPORT MEDIUM MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION
EXHIBIT 4 IMPACT OF LAUNCHES OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS
EXHIBIT 5 IMPACT OF INCREASING PREVALENCE OF INFECTIOUS DISEASES
EXHIBIT 6 IMPACT OF SURGE IN COVID-19 INFECTIONS
EXHIBIT 7 DAILY CORONAVIRUS CASES 2020-2022 (MILLION)
EXHIBIT 8 COVID-19 TEST PER MILLION CASES IN FEB 2022
EXHIBIT 9 IMPACT OF INCREASE IN DIAGNOSIS RATES FOR VIRAL INFECTIOUS DISEASES
EXHIBIT 10 IMPACT OF VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS
EXHIBIT 11 IMPACT OF FALSE-NEGATIVE RESULTS IN BORDERLINE CASES
EXHIBIT 12 VIRAL TRANSPORT MEDIA: FACTORS AFFECTING NEGATIVE/ FALSE RESULT
EXHIBIT 13 IMPACT OF LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS
EXHIBIT 14 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 15 FIVE FORCES ANALYSIS 2021
EXHIBIT 16 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027
EXHIBIT 17 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2022-2027
EXHIBIT 18 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: INCREMENTAL GROWTH
EXHIBIT 19 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: ABSOLUTE GROWTH
EXHIBIT 20 GLOBAL VIRAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 21 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 22 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 23 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET 2021–2027 ($ MILLION)
EXHIBIT 24 GLOBAL TREND IN CASE NOTIFICATION OF PEOPLE NEWLY DIAGNOSED WITH TB 2016-2020 (PER YEAR IN MILLION)
EXHIBIT 25 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 26 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET 2021–2027 ($ MILLION)
EXHIBIT 27 INCREMENTAL GROWTH BY USAGE 2021 & 2027
EXHIBIT 28 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USES 2022-2027
EXHIBIT 29 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: INCREMENTAL GROWTH
EXHIBIT 30 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: ABSOLUTE GROWTH
EXHIBIT 31 GLOBAL DIAGNOSIS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 32 GLOBAL PREVALENCE OF STI VIRAL DISEASES 2020 (MILLION)
EXHIBIT 33 GLOBAL DIAGNOSIS USAGE MARKET 2021–2027 ($ MILLION)
EXHIBIT 34 GLOBAL PRE-CLINICAL TESTING MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 35 GLOBAL PRE-CLINICAL TESTING MARKET 2021–2027 ($ MILLION)
EXHIBIT 36 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027
EXHIBIT 37 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2022-2027
EXHIBIT 38 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: INCREMENTAL GROWTH
EXHIBIT 39 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL INFLUENZA & COVID-19 MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL INFLUENZA & COVID-19 INDICATION MARKET 2021–2027 ($ MILLION)
EXHIBIT 43 GLOBAL HERPES SIMPLEX VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL HERPES SIMPLEX VIRUS INDICATION MARKET 2021–2027 ($ MILLION)
EXHIBIT 45 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET 2021–2027 ($ MILLION)
EXHIBIT 47 GLOBAL VARICELLA-ZOSTER VIRUS MARKET 2021–2027 ($ MILLION)
EXHIBIT 48 GLOBAL VARICELLA ZOSTER VIRUS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL OTHERS INDICATION MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL OTHER VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 51 INCREMENTAL GROWTH BY END-USER 2021 C& 2027
EXHIBIT 52 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2022-2027
EXHIBIT 53 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 54 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 57 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 58 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 59 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL OTHERS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 61 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 62 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2022-2027
EXHIBIT 63 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 64 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 65 VIRAL TRANSPORT MEDIUM MARKET NORTH AMERICA: KEY COUNTRIES 2019 ($ MILLION)
EXHIBIT 66 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 67 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 68 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 69 US VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 70 CANADA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 71 VIRAL TRANSPORT MEDIUM MARKET EUROPE: KEY COUNTRIES 2019 ($ MILLION)
EXHIBIT 72 EUROPE VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 EUROPE VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 74 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 75 UK: VARICELLA AGE-SPECIFIC ANNUAL COMMUNITY INCIDENTS PER 100,000
EXHIBIT 76 UK VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 77 FRANCE: AGE-SPECIFIC ANNUAL COMMUNITY INCIDENCE OF VARICELLA PER 100,000
EXHIBIT 78 FRANCE VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 79 ITALY: INCIDENCE OF HERPES BY AGE GROUP & GENDER
EXHIBIT 80 ITALY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 81 GERMANY: TOTAL COVID-19 CASES AUG 2021–FEB 2022 (MILLION)
EXHIBIT 82 GERMANY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 83 SPAIN VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 84 VIRAL TRANSPORT MEDIUM MARKET APAC: KEY COUNTRIES 2019 ($ MILLION)
EXHIBIT 85 APAC VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 86 APAC VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 87 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 88 CHINA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 89 JAPAN VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 90 INDIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 91 AGE STANDARDIZED HOSPITALIZATION RATE NOTIFIABLE COMMUNICATION DISEASES 2013–2017
EXHIBIT 92 AUSTRALIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 93 SOUTH KOREA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 94 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)
EXHIBIT 95 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 96 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 97 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 98 PREVALENCE OF HERPES ZOSTER IN BRAZIL (VIA REGION) 2021
EXHIBIT 99 BRAZIL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 100 MEXICO VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 101 ARGENTINA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 102 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)
EXHIBIT 103 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 104 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 105 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 106 TURKEY: INCIDENT RATE OF HERPES ZOSTER WITH RESPECT TO AGE (2011–2019) (PER 100,000 PEOPLE)
EXHIBIT 107 TURKEY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 108 SAUDI ARABIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 109 SOUTH AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)
EXHIBIT 110 THERMO FISHER SCIENTIFIC: ANNUAL REVENUE 2018–2020 ($ BILLION)
EXHIBIT 111 THERMO FISHER SCIENTIFIC ANNUAL REVENUE BY SEGMENT 2020 (%)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 SOME OF COVID-19 TRANSPORT MEDIA MANUFACTURER AND PRODUCTS
TABLE 4 COVID-19 TEST DONE DURING 2020-2022
TABLE 5 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 6 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 7 UNIVERSAL TRANSPORT MEDIA KIT & MANUFACTURER
TABLE 8 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 9 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 10 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 11 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 12 OVERALL COVID-19 DIAGNOSIS TEST BY REGION IN 2022
TABLE 13 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 14 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 15 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 16 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 17 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 18 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 19 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 20 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 21 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 22 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 23 VIRAL TRANSPORT MEDIUM VARICELLA-ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 24 VIRAL TRANSPORT MEDIUM VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 25 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 26 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 27 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 28 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 29 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 30 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 31 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 32 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 33 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 34 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)
TABLE 35 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 36 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 37 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 38 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 39 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 40 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 41 US: MEDICAL DIAGNOSTICS LABS
TABLE 42 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 43 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)
TABLE 44 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 45 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 46 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 47 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 48 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 49 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 50 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 51 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)
TABLE 52 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 53 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 54 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 55 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 56 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 57 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 58 CHINA: LABORATORY DETECTION OF ILI SPECIMENS WEEK 15 IN 2019.
TABLE 59 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 60 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)
TABLE 61 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 62 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 63 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 64 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 65 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 66 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 67 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021−2027 ($ MILLION)
TABLE 68 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021−2027 (%)
TABLE 69 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 70 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 71 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 72 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 73 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 74 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 75 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 76 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 77 BD: MAJOR PRODUCT OFFERINGS
TABLE 78 HARDY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 79 HIMEDIA LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 80 LABORATORY CORPORATION OF AMERICA: MAJOR PRODUCT OFFERINGS
TABLE 81 PURITAN MEDICAL PRODUCTS: MAJOR PRODUCT OFFERINGS
TABLE 82 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 83 VIRCELL: MAJOR PRODUCT OFFERINGS
TABLE 84 AB MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 85 ACCUGENE USA: MAJOR PRODUCT OFFERINGS
TABLE 86 APICAL SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 87 AZOOKA LABS: MAJOR PRODUCT OFFERINGS
TABLE 88 BIOMED DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 89 BIOBOAVISTA: MAJOR PRODUCT OFFERINGS
TABLE 90 BIOGENEX LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 91 BIOLOGIX GROUP: MAJOR PRODUCT OFFERINGS
TABLE 92 BIOCOMMA: MAJOR PRODUCT OFFERINGS
TABLE 93 CHARM SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 94 CREATIVE LIFE SCIENCES CO. LTD.: MAJOR PRODUCT OFFERINGS
TABLE 95 CITOTEST LABWARE MANUFACTURING: MAJOR PRODUCT OFFERINGS
TABLE 96 CPT MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 97 COPAN DIAGNOSTIC INC.: MAJOR PRODUCT OFFERINGS
TABLE 98 DIASORIN MOLECULAR: MAJOR PRODUCT OFFERINGS
TABLE 99 EKF DIAGNOSTIC: MAJOR PRODUCT OFFERINGS
TABLE 100 ENSOL BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 101 GEMINI BIOPRODUCTS: MAJOR PRODUCT OFFERINGS
TABLE 102 GENERAL BIOLOGICS: MAJOR PRODUCT OFFERINGS
TABLE 103 GENTUERI: MAJOR PRODUCT OFFERINGS
TABLE 104 GENESIS LIFETECH MARKETING: MAJOR PRODUCT OFFERINGS
TABLE 105 HAN CHANG MEDIC: MAJOR PRODUCT OFFERINGS
TABLE 106 HEBEI CHAORAN MEDICAL INSTRUMENTS: MAJOR PRODUCT OFFERINGS
TABLE 107 KSL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 108 LUCENCE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 109 LAUNCHWORKS: MAJOR PRODUCT OFFERINGS
TABLE 110 LIOFILCHEM: MAJOR PRODUCT OFFERINGS
TABLE 111 MEDICAL WIRE & EQUIPMENT: MAJOR PRODUCT OFFERINGS
TABLE 112 MIRACLEAN TECHNOLOGY (MANTACC): MAJOR PRODUCT OFFERINGS
TABLE 113 METADESIGN SOLUTIONS: MAJOR PRODUCT OFFERINGS
TABLE 114 MANILA HEALTHTEK: MAJOR PRODUCT OFFERINGS
TABLE 115 MATTEK: MAJOR PRODUCT OFFERINGS
TABLE 116 NODFORD INTERNATIONAL: MAJOR PRODUCT OFFERINGS
TABLE 117 STARPLEX SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 118 SANSURE BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 119 TITAN BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 120 VEGAS BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 121 ZYBIO: MAJOR PRODUCT OFFERINGS
TABLE 122 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 123 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 124 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)
TABLE 125 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)
TABLE 126 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)
TABLE 127 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)
TABLE 128 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)
TABLE 129 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)
TABLE 130 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 131 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)
TABLE 132 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 133 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 134 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 135 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 136 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 137 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 138 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 139 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 140 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 141 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 142 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 143 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 144 GLOBAL HERPES MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 145 GLOBAL HERPES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 146 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 147 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 148 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 149 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 150 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 151 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 152 GLOBAL LABS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 153 GLOBAL LABS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 154 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 155 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 156 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 157 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021−2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
